Cover Image
市場調查報告書

肺高血壓的全球市場:2015∼2019年

Pulmonary Hypertension - Global Market Research 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 341190
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
肺高血壓的全球市場:2015∼2019年 Pulmonary Hypertension - Global Market Research 2015-2019
出版日期: 2015年09月30日 內容資訊: 英文 65 Pages
簡介

肺高血壓是影響由肺輸送非氧化血到心臟的肺動脈的疾病。因肺動脈狹窄或堵塞而引起肺部高血壓。要到病情嚴重才會有症狀出現。主要原因有肺氣腫、結締組織障礙、肺內血栓、睡眠呼吸中止症等。全球肺高血壓市場預測在2014∼2019年間將以年複合成長率2.92%擴大。

本報告提供全球肺高血壓市場現狀及2015∼2019年的成長預測相關調查,為您彙整市場規模,收益趨勢,各產品,各地區趨勢,及主要供應商簡介等資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第6章 產品研發線

第7章 各製劑市場區隔

  • 口服
  • 注射
  • 吸入

第8章 各作用機制市場區隔

  • 內皮素受體拮抗劑
  • 前列環素類似物
  • PDE抑制劑
  • 可溶性鳥苷酸環化酶刺激

第9章 各地區市場區隔

第10章 推動市場的要素

  • 肺高血壓的發病率上升
  • 患者支援計劃
  • 新的疾病調節療法
  • 未滿足需求

第11章 推動市場要素的影響

第12章 市場課題

  • 專利的失效
  • 患者適合性低
  • 供應商間的激烈競爭

第13章 促進要素與課題的影響

第14章 市場趨勢

  • 對聯合治療的關注
  • 高血壓的意識提升
  • 策略性聯盟

第15章 供應商環境

  • 競爭模式
  • 最新趨勢
  • 合併·收購
  • 市場佔有率分析:2014年
  • 其他值得注意的供應商

第16章 主要供應商分析

  • Actelion Pharmaceuticals
  • Bayer HealthCare
  • GSK
  • United Therapeutics

第17章 附錄

第18章 關於Technavio

圖表

目錄
Product Code: IRTNTR7554

About pulmonary hypertension

Pulmonary hypertension is a rare disorder that affects the pulmonary arteries carrying deoxygenated blood to the lungs from the heart. The narrowing or blockage of pulmonary arteries will lead to pulmonary hypertension. Symptoms of the disease do not occur until the disease becomes severe. Certain causes of pulmonary hypertension include emphysema, connective tissue disorders, blood clots in lungs, and sleep apnea. Pulmonary hypertension may sometimes lead to several chronic illnesses, such as kidney failure (renal failure), heart failure, aneurysm, heart attack, or, stroke. Endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase inhibitors, and sGC stimulators are popular drug therapeutic classes available for the treatment of pulmonary hypertension.

Technavio's analysts forecast the global pulmonary hypertension market to grow at a CAGR of 2.92% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global pulmonary hypertension market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of pulmonary hypertension.

Technavio's report, Global Pulmonary Hypertension Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

Key vendors

  • Actelion
  • Bayer
  • GlaxoSmithKline
  • United Therapeutics

Other Prominent Vendors

  • Aires Pharmaceuticals
  • Arena Pharmaceuticals
  • Bial
  • DEKA
  • Dong-A ST
  • Gilead
  • Merck
  • Northern Therapeutics
  • Novartis
  • Pfizer
  • PhaseBio

Key market driver

  • Growing incidence of pulmonary hypertension
  • For a full, detailed list, view our report

Key market challenge

  • Patent expiry
  • For a full, detailed list, view our report

Key market trend

  • Increased focus on combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Pipeline portfolio

  • Key information of pipeline candidates

PART 07: Market segmentation by type of formulation

  • Oral
  • Injection
  • Inhalation

PART 08: Market segmentation by mechanism of action

  • Endothelin receptor antagonist
  • Prostacyclin analogs
  • Phosphodiesterase inhibitors
  • Soluble guanylate cyclase stimulators

PART 09: Geographical segmentation

PART 10: Market drivers

  • Increase in incidence of pulmonary hypertension
  • Patient assistance programs
  • New disease-modifying therapies
  • Unmet medical needs

PART 11: Impact of drivers

PART 12: Market challenges

  • Patent expiry
  • Poor patient compliance
  • Intense competition among vendors

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Increased focus on combination therapies
  • Increase in awareness of hypertension
  • Strategic alliances

PART 15: Vendor landscape

  • Competitive scenario
  • Key news
  • Mergers and acquisitions
  • Market share analysis 2014
  • Other prominent vendors

PART 16: Key vendor analysis

  • Actelion Pharmaceuticals
  • Bayer HealthCare
  • GSK
  • United Therapeutics

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global pulmonary hypertension market: 2014-2019 ($ billions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Pipeline portfolio
  • Exhibit 05: Market segmentation by type of formulation
  • Exhibit 06: Market segmentation by type of formulation 2014
  • Exhibit 07: Market segmentation by mechanism of action
  • Exhibit 08: Market segmentation by mechanism of action 2014
  • Exhibit 09: Market segmentation by region 2014
  • Exhibit 10: Impact of drivers
  • Exhibit 11: Revatio sales in the US 2011-2014 ($ millions)
  • Exhibit 12: Impact of drivers and challenges
  • Exhibit 13: Actelion Pharmaceuticals : Key takeaways
  • Exhibit 14: Tracleer: Global sales 2011-2014 ($ billions)
  • Exhibit 15: Opsumit: Global sales 2013-2015 H1 ($ millions)
  • Exhibit 16: Ventavis: Global sales 2011-2014 ($ millions)
  • Exhibit 17: Veletri: Global sales 2011-2014 ($ millions)
  • Exhibit 18: United Therapeutics: Key takeaways
  • Exhibit 19: Remodulin: Global sales 2011-2014 ($ millions)
  • Exhibit 20: Tyvaso: Global sales 2011-2014 ($ millions)
  • Exhibit 21: Adcirca: Global sales 2011-2014 ($ millions)
  • Exhibit 22: Orenitram: Global sales 2014-2015 H2 ($ millions)
  • Exhibit 23: GlaxoSmithKline: Key takeaways
  • Exhibit 24: Flolan: Global sales 2012-2013 ($ millions)
  • Exhibit 25: Bayer: Key takeaways
  • Exhibit 26: Adempas: Global sales 2013-2014 ($ millions)
  • Exhibit 27: Actelion Pharmaceuticals: Product segmentation
  • Exhibit 28: Actelion Pharmaceuticals: Business segmentation by revenue 2014
  • Exhibit 29: Actelion Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
  • Exhibit 30: Actelion Pharmaceuticals: Geographical segmentation by revenue 2014
  • Exhibit 31: United Therapeutics: Product segmentation by revenue 2014
  • Exhibit 32: United Therapeutics: Product segmentation by revenue 2014 ($ millions)
  • Exhibit 33: United Therapeutics: Geographical segmentation by revenue 2014
Back to Top